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Abstract Multiple myeloma (MM) is characterized by a
monoclonal plasma cell population in the bone marrow.
Lytic lesions occur in up to 90 % of patients. For many years,
whole-body X-ray (WBX) was the method of choice for de-
tecting skeleton abnormalities. However, the value ofWBX in
relapsing disease is limited because lesions persist post-treat-
ment, which restricts the capacity to distinguish between old,
inactive skeletal lesions and new, active ones. Therefore, al-
ternative techniques are necessary to visualize disease activity.
Modern imaging techniques such as magnetic resonance im-
aging, positron emission tomography and computed tomogra-
phy offer superior detection of myeloma bone disease and
extramedullary manifestations. In particular, the properties of
nuclear imaging enable the identification of disease activity by
directly targeting the specific cellular properties of malignant
plasma cells. In this review, an overview is provided of the
effectiveness of radiopharmaceuticals that target metabolism,
surface receptors and angiogenesis. The available literature
data for commonly used nuclear imaging tracers, the promis-
ing first results of new tracers, and our pilot work indicate that
a number of these radiopharmaceutical applications can be
used effectively for staging and responsemonitoring of relaps-
ing MM patients. Moreover, some tracers can potentially be
used for radio immunotherapy.
Keywords Relapsingmultiplemyeloma .
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Introduction
Multiple myeloma, diagnosis and treatment
Multiple myeloma (MM) is a disease characterized by a
monoclonal plasma cell population in bone marrow. In most
cases, the diagnosis of MM is based on the presence of a
monoclonal M-protein or free-light chain in the blood and at
least 10 % plasma cells in the bone marrow. Treatment is
initiated when MM is symptomatic according to CRAB fea-
tures: hypercalcemia (C), renal impairment (R), anemia (A) or
bone lesions (B). Currently, patients with more than 60 %
monoclonal plasma cells in their bone marrow, a free-light
chain ratio greater than 100, or more than 1 focal bone or bone
marrow lesion on the magnetic resonance imaging (MRI) are
classified as high risk for development of MM, and should
also receive treatment [1].
First-line treatment for patients younger than 70 years and
eligible for autologous stem cell transplantation (ASCT) con-
sists of induction chemotherapy, including a proteasoom in-
hibitor or an immunomodulator agent like bortezomib,
lenalidomide or thalidomide, followed by ASCT [2, 3].
Patients ineligible for ASCT are treated with a combination
of melphalan, prednisolone and a novel agent, or with the
combination of lenalidomide and dexamethasone [4, 5].
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Following the introduction of these regimens, the overall sur-
vival (OS) improved considerably: the 5-year OS for younger
MM patients is now 70 %, and for older patients, 41 % [6].
Multiple myeloma and imaging
Whole-body X-ray, MRI and low-dose CT scan
Asymptomatic MM is distinguished from symptomatic MM
through the CRAB criteria. Bone lesions play an important
role since lytic bone lesions develop in 90 % of the patients
during the disease. These lesions, are an important cause of
morbidity, resulting in pain and, in some cases, in pathologic
fractures [7]. Lytic bone lesions are the result of increased
bone resorption and reduced bone formation [8]. Detecting
bone lesions is an important part for the diagnosis of symp-
tomatic MM since having bone lesions means treatment is
indicated. This highlights the need for accurate investigation
of bone disease. Until recently, whole-bodyX-ray (WBX) was
the method of choice. This technique has several limitations: it
can only detect lesions that have lost more than 30 % of the
trabecular bone [7], and no extramedullary disease can be
shown. The value in relapsing disease is limited since lesions
persist post-treatment. No distinction can be made between
old vs. new lesions and, therefore, it is of limited value for
disease monitoring.
In recent years, alternative techniques have been developed
to visualize MM activity. Low-dose whole-body computed
tomography (WB-CT), MRI and positron emission tomogra-
phy (PET/CT) are introduced for the detection of (active) bone
lesions. The latest update from the International Myeloma
Working Group defines that for the diagnosis of symptomatic
MM, evidence of one or more (>5 mm in size) osteolytic bone
destruction lesions seen on CT or PET/CT does fulfill the
criteria for bone disease, thereby fulfilling the CRAB criteria
[1]. The guideline also recommends performing a PET/CT,
CTorMRI of the whole body or spine in all patients suspected
of asymptomatic MM to exclude bone involvement [1].
Nowadays, MRI and WB-CT scanning have been implement-
ed in many parts of the world for detecting myeloma lesions.
WB-CT scanning has a higher detection rate of lytic lesions
compared with WBX but, in some studies, lesions in the skull
and ribs were less well-detected with WB-CT, while other
studies suggested a better detection rate with WB-CT [9,
10]. An other advantage of WB-CT is the fact that radiation
exposure is comparable with WBX, and no intravenous con-
trast is needed [10].
MRI is used for detection of spinal cord compression and to
differentiate myeloma from non-myeloma vertebral fractures.
MRI has a high detecting rate of bone marrow involvement.
MRI provides the opportunity to visualize bone marrow infil-
tration rather than defining osteolytic lesions. Therefore, in
newly diagnosed patients, MRI may be less helpful since it
detects bone lesions earlier than the myeloma-related bone
destruction has occurred. In case of monoclonal gammapathy
of unknown significance (MGUS), asymptomatic MM or sol-
itary plasmacytoma of the bone, MRI can be used to distin-
guish a high-risk patient for developing symptomatic MM.
Patients with more than one focal lesion on the MRI are clas-
sified as high risk for development of MM [10, 11].
An alternative manner of imaging MM activity is to target
cellular properties of MM cells or micro-environment which
can be accomplished by using different radio-labeled com-
pounds to visualize the affected skeleton areas.
Target mechanism in nuclear imaging
PET imaging is now widely used for the detection and
follow-up of malignant disorders. In MM, PET tracers are
used especially for detecting medullary and extramedullary
disease. These nuclear tracers can also provide information
about the degree of uptake by the lesions of interest, which is
indicated by calculation of the standardized uptake value
(SUV). In addition, PET scanning has shown promise for
monitoring treatment response, since increase or decrease
can be visualized and/or calculated compared to a baseline
scan [12]. Recently, various specific PET tracers have been
developed which might be useful in the workup of patients
with newly diagnosed and relapsing MM. In the present re-
view, we evaluate several nuclear tracers and nuclear imaging
techniques as defined by their primary target (shown in
Table 1 and Fig. 1).
Cell metabolism
Glucose
[18 F]-fluorodeoxyglucose PET ([18 F]-FDG-PET) uses en-
hanced glucose metabolic activity to visualize areas of inter-
est [13]. [18 F]-FDG, a glucose analogue, is actively
transported into cells mediated by a group of structurally
related glucose transporter proteins (GLUT). Tumor cells,
including MM cells, show increased numbers of these glu-
cose transporters, particularly GLUT-1 and GLUT-3 [14].
Glucose and [18 F]-FDG are phosphorylated intracellularly
by hexokinase. In contrast to glucose, [18 F]-FDG undergoes
no further metabolism in the glucose pathway and becomes
trapped intracellularly as [18 F]-FDG-6-phosphate [15]. The
use of [18 F]-FDG-PET as a baseline scan has been studied
extensively in newly diagnosed MM patients. Based on the
number of focal lesions and the maximum SUV (SUVmax),
[18 F]-FDG-PET detects more lesions compared to WBX [9].
In addition, follow-up [18 F]-FDG-PET scans can be used to
monitor treatment response and are of prognostic value for
survival [12]. Complete normalization of the [18 F]-FDG-





































Table 1 Various nuclear imaging
techniques [PET and single-
photon emission computed
tomography (SPECT)] and their
targets
Mechanism of action Tracer Target
Cell metabolism
Glucose [18 F]-FDG Glucose uptake
Amino acid [11C]-MET Methionine
[18 F]-FAMT L-type aminoacid transporter 1
Nucleotide [18 F]-FLT Activity of thymidine kinase
[11C] -4DST Activity of thymidine kinase
Membrane metabolism [11C]-ACT Acetate/fatty acid synthesis
[11C]-choline Choline
Receptor targeting
Somatostatin receptor scintigraphy [111In]-pentetreotide Somatostatin receptor






Hypoxia [18 F]-FAZA Hypoxia
Angiogenesis [89Zr]-bevacizumab Circulating VEGF
Legend: [18 F]-FDG: [18 F]-fluorodeoxyglucose, [11C]-MET: [11C]-Methionine, [18 F]-FAMT: [18 F]-alpha-
methyltyrosine, [18 F]-FLT: [18 F]-fluoro-3-deoxy-L-thymidine, [11C]-4DST: Methyl-11C-40- thiothymidine,
[11C]-ACT: [11C]-acetate, [18 F]-FAZA: 1-α-D: −(5-deoxy-5-[18 F]-fluoroarabinofuranosyl)-2-nitroimidazole,
VEGF: vascular endothelial growth factor, CXCR4: chemokine receptor 4, VLA-4: very late antigen-4
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PET scan before and after ASCT correlates with both im-
proved progression-free survival (PFS) and overall survival
(OS) [12]. This imaging technique may also be useful in
patients with relapsing MM since it is not hampered by the
presence of pre-existing skeletal defects due to it visualizing
areas of enhanced metabolic activity [9, 16–19]. In relapsing
MM patients, only a few studies have been performed with
[18 F]-FDG-PET [14, 20–22]. Disease activity is shown on
the [18 F]-FDG-PET (Table 2A) in the majority of MM pa-
tients. A significantly higher number of positive lesions has
been detected relative to WBX [14]. In about 25 % of the
patients with relapsing disease, no defects on [18 F]-FDG-
PET scans are shown, despite the presence of active disease.
Comparable results have been reported in newly diagnosed
MM patients, with 24 % of the patients having a negative
[18 F]-FDG-PET scan (Table 2A) [12]. This is probably due
to a diffuse distribution of malignant plasma cells in the skel-
eton. Skull lesions smaller than 1 cm are especially difficult to
detect with [18 F]-FDG-PET [19] because of the high phys-
iological uptake in the brain tissue.
Improvements have been made regarding uptake mea-
surements with [18 F]-FDG-PET. Total lesion glycolysis
(TLG) and metabolic tumor volume (MTV) can be
calculated from [18 F]-FDG-PET and might be a more
accurate measurement than the conventional measure-
ments predicting overall tumor burden of focal lesions in
MM. In a recent study of newly diagnosed MM patients,
[18 F]-FDG-PET was performed at baseline (Table 2A).
In this study, a TLG >620 g and MTV >210 cm [3] was
found to be a significant predictor for a poorer PFS and
OS [23]. Combining TLG and MTV with other risk fac-
tors like gene expression profiling and International
Staging System (ISS) stage resulted in the identification
of a high-risk subgroup [23].
The Italian group presented guidelines for uniforming
[18 F]-FDG-PET quantification by using a five-point scale
including: the metabolic state of the bone marrow, number
and site of focal [18 F]-FDG-PET-positive lesions with or
without osteolytic characteristics, presence and site of
extramedullary disease, presence of paramedullary disease (a
bone lesion involving surrounding soft tissues with bone cor-
tical interruption), and presence of fractures. The visual degree
of uptake is defined for the target lesion and extramedullary
lesions according to the Deauville criteria [24]. In a small
series, this five-point scale seemed reproducible and can be
used for comparing [18 F]-FDG-PET scans from baseline to
Table 2 [18 F]-FDG-PET in
MM compared to various nuclear
imaging techniques (PET and
SPECT)
A
Study Tracer n MM % pos [18 F]-FDG-PET
De Waal 2015 [18 F]-FDG 44 R 82 %
Lapa 2014 [18 F]-FDG 37 R 76 %
Zamagni 2011 [18 F]-FDG 192 ND 76 %
McDonald 2016 [18 F]-FDG 192 ND 68 %
B
Study Tracer n MM pos scan vs pos [18 F]-FDG-PET (%)
Okasaki 2015 [11C]-MET 10 R 100 % vs 60 %
Lapa 2016 [11C]-MET 43 32 R 91 % vs 77 %
Isoda 2012 [18 F]-FAMT 11 R 73 % vs 73 %
Agool A 2006 [18 F]-FLT 2 R very low uptake
Okasaki 2015 11C] -4DST 10 R 80 % vs 60 %
Lin C 2014 [11C]-ACT 15 ND 86 % vs 67 %
Nanni C 2007 11C]-Choline 4 R 100 % vs 100 %
Cassou-Mounat 2016 11C]-Choline 21 R 71 % vs 71 %
De Waal 2012 111In]-Pentetreotide 18 R 52 % vs 71 %
Philipp-Abbrederis K 2015 68Ga]-Pentixafor 14 R 71 % vs 64 %
Fonti R 2015 99mTc]-Sestamibi 27 ND 89 % vs 97 %
De Waal 2015 [18 F]-FAZA 5 R negative scan
De Waal, unpublised 89Zr]-Bevacizumab 5 R neagtive scan
Legend A: [18 F]-FDG-PET in relapsing MM. B: Studies with different nuclear imaging techniques (PET and
SPECT) in MM patients compared to [18 F]-FDG-PET before treatment was started.
[18 F]-FDG: [18 F]-fluorodeoxyglucose, MM: multiple myeloma, [11C]-MET: [11C]-methionine, [18 F]-FAMT:
[18 F]-alpha-methyltyrosine, [18 F]-FLT: [18 F]-fluoro-3-deoxy-L-thymidine, [11C] -4DST: methyl-11C-40-
thiothymidine, [11C]-ACT: [11C]-acetate, [18 F]-FAZA: 1-α-D: −(5-deoxy-5-[18 F]-fluoroarabinofuranosyl)-
2-nitroimidazole; N: total number of patients studied; R: relapsed MM, ND: newly diagnosed MM.
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scans after treatment; furthermore, it provides a guideline to
uniform research data [24].
Amino acids
Methionine, an amino acid required for protein synthesis, can
be used for PET scanning. [11C]-Methionine ([11C]-MET) is
frequently used for imaging brain tumours, since the physio-
logical background uptake of [11C]-MET is low in the brain.
Due to the active protein synthesis by the malignant plasma
cells, this might also be a useful tracer for MM. In several
studies, [11C]-MET was compared with [18 F]-FDG-PET
(Table 2B) [25, 26]. Compared to [18 F]-FDG-PET, more
lesions were detected with [11C]-MET, especially when a
low number of aberrant plasma cells were present in the bone
marrow (<30 %) [25]. A limitation for widespread use of
[11C]-MET is the short half-life of approximately 20 minutes,
necessitating production by an on-site cyclotron.
The amino acid transporter L-type amino acid transporter 1
(LAT-1) is overexpressed in a number of tumors including
MM. LAT-1 provides a transporter function for protein syn-
thesis. The amino acid tracer [18 F]-alpha-methyltyrosine
([18 F]-FAMT) is also transported by LAT-1. The uptake of
this tracer correlates with LAT-1 expression [27]. In relapsing
MM patients, a comparison has been made between [18 F]-
FAMTand [18 F]-FDG-PET. A comparable number of lesions
were detected with both imaging techniques, but the SUVmax
was significantly lower in FAMT-PET compared to [18 F]-
FDG-PET (Table 2) [27].
DNA proliferation marker
Thymidine, a DNA nucleoside required for DNA synthesis,
can also be used as a tracer. Fluorothymidine is an analogue of
the nucleoside thymidine (deoxythymidine) and can be la-
belled to produce [18 F]-fluoro-3-deoxy-L-thymidine
([18 F]-FLT). FLT is transported into the cell and is a substrate
for thymidine kinase-1 (TK1), which is related to DNA syn-
thesis and is, therefore, a surrogate marker for cell prolifera-
tion [28]. Using [18 F]-FLT PETscanning for solid malignan-
cy, a high bone marrow background activity has been demon-
strated, which indicates the proliferative activity of the hema-
topoietic cells in the bone marrow cavity [29]. Patients with
MM were included in a pilot study using [18 F]-FLT with
haematological malignancies. Areas with skeletal lesions
showed a very low uptake of [18 F]-FLT compared to
non-affected areas, which is in line with the low proliferative
activity of MM cells [30]. Follow up scans with this tracer
may be difficult since it has been shown that bone marrow
cells undergo a phenotypic shift after chemotherapy and au-
tologous stem cell transplantation, thereby altering their cy-
cling time and the uptake seen on the [18 F]-FLT-PET scan
[31]. The new tracer methyl-[11C]-40-thiothymidine ([11C]-
4DST) has shown more positive findings. [11C]-4DST is
more stable than [18 F]-FLT. Once [11C]-4DST is incorpo-
rated into DNA, de-phosphorylation occurs relatively rarely,
unlike [18 F]-FLT. This has also been shown in a study of
MM patients in which [11C]-4DST showed more positive
findings per patient than [18 F]-FDG-PET, particularly in
patients with low numbers of bone marrow plasma cells
(Table 2B) [25].
Membrane
Acetate is an important metabolite that is used to synthesize
amino acids, nucleotides and fatty acids. When ligated to co-
enzyme A (acetyl-CoA), it can be converted into fatty acids
[32]. [11C]-acetate ([11C]-ACT) can be, like the natural pre-
cursor acetate, converted into fatty acids. In cell lines, it has
been demonstrated that MM cells have a higher metabolic
activity involving free fatty acids [28]. In newly diagnosed
MM patients, [11C]-ACT PET identified more focal lesions
than [18 F]-FDG PET (Table 2B) [33]. This result is promis-
ing, but needs to be verified in a larger number of patients,
including relapsing MM patients. An additional player in fatty
acid metabolism is choline, which is phosphorylated by cho-
line kinase and incorporated into various phospholipids. In
prostate cancer, [11C] or [18 F]-choline has frequently been
used for monitoring disease activity. In two studies with
[11C]-choline PET scanning in MM patients, the number of
positive scans were similar when [11C]-choline was com-
pared with [18 F]-FDG-PET, but more focal lesions were de-
tected with [11C]-choline than with [18 F]-FDG-PET) [34,
35].
Cluster of differentiation 38 (CD38), which is a glycopro-
tein functioning in cell adhesion, signal transduction and cal-
cium signaling [36], is highly expressed onmyeloma cells, but
at relatively low levels on normal hematopoietic cells and in
some tissues of non-hematopoietic origin, like lung tissue.
Currently, an anti-CD38 human monoclonal antibody,
daratumab, has been developed. This drug is promising in
the treatment of MM. Treatment with daratumumab mono-
therapy in relapsed and refractory MM patients did have a
significant effect on PFS [36]. Phase 3 trials combining
daratumumab with conventional treatments such as
bortezomib and lenalidomide are ongoing. Use of radio-
labeled anti-CD38 could be a promising approach not only
for diagnostic purposes and treatment monitoring, but it might
also be used in the context of radio-immunotherapy due to the
restricted expression of CD38 on normal tissues. Preclinical
studies have already been performed in xenograft mice
models with radio-immunoconjugates consisting of the α-
emitter [213Bi] coupled to the anti-CD38 monoclonal anti-
body, with a significant targeting of CD38 [37].
CD138, or syndecan-1, is a member of the syndecan fam-
ily, expressed by epithelial cells, precursor B cells, and normal
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plasma cells. CD138 is highly expressed on myeloma cells.
Phase I–II studies have been initiated with anti-CD138, called
Indatuximab [38, 39]. Alpha-radio-immunotherapy treatment
using a [213Bi]-labelled anti-mouse CD138 antibody has
been performed in mouse models, showing promising results.
Mice treated with [213Bi]-CD138 had a longer median sur-
vival than the control group [40].
Receptor targeting
In vitro studies with plasma cell lines have shown that somato-
statin receptors, especially subtypes 1, 2 and 5, are highly
expressed on MM cells [41]. Somatostatin receptor scintigra-
phy (SRS) using the single-photon emission computed to-
mography (SPECT) tracer [111In]-pentetreotide is able to vi-
sualize somatostatin receptors, especially subtypes 2 and 5
[42]. SPECT has, by definition, a lower spatial resolution
and less quantification possibilities, compared to PET.
Studies with SRS in MM patients have been performed spe-
cifically in relapsing MM patients. A positive SRS scan was
reported in 83 % of the patients, which is significantly higher
than the results obtained with WBX [43, 44]. However, when
SRS was compared to [18 F]-FDG-PET, the latter identified
significantly more focal lesions [44], which may be explained
by the better resolution of PET compared to SPECT. SRS is
also used in the workup of neuroendocrine tumors (NET). In
this context, [68Ga]-DOTA-TOC/TATE/NOC/lanreotide
PET/CT is used, which has superior resolution and, hence,
better sensitivity than the conventional SRS, thereby replacing
SRS for staging NET [45]. Considering these properties,
[68Ga]-DOTA subtypes might also be useful for diagnostic
purposes in MM.
Chemokine receptor 4 (CXCR4) is expressed on hemato-
poietic stem and progenitor cells residing in the bone marrow
niche, which has an important function in the homing of these
cells to the bone marrow compartment. Disrupting this inter-
action by Plerixafor, a CXCR4 antagonist, results in mobili-
zation of stem cells out of the bone marrow niche, a property
used for stem cell mobilization. CXCR4 is also expressed on
other cell types of the hematopoietic system, including plasma
cells. Approximately 50 % of the MM cells express CXCR4
in high density [46]. [68Ga]-pentixafor is a labelled peptide
with high affinity for CXCR4, which has been studied in
relapsing MM patients in comparison to [18 F]-FDG-PET.
The results showed that a high number of the MM patients
have a positive [68Ga]-pentixafor scan [46] (Table 2B). Due
to these promising results, the anti-CXCR4 antibody has been
labeled with [177Lu]-pentixather or [90Y]-pentixather with
the aim of performing radio-immunotherapy. Recently, three
heavily pretreated myeloma patients were treated with
[177Lu]-pentixather or [90Y]-pentixather after CXCR4 ex-
pression was confirmed with a [68Ga]-pentixafor PET scan.
Two patients responded to treatment, showing a decrease in
free-light chain ratio and a reduction of SUVmax on the
[18 F]-FDG-PET scan. The third patient died due to sepsis
3 weeks after [177Lu]-pentixather therapy. PFS was short,
and ranged between 3 and 6 months [47]. Based on these pilot
studies, [68Ga]-pentixafor scanning might be used to select
patients treatment with radiolabeled [68Ga]-pentixafor and to
monitor the effects of therapy [47].
Another membrane receptor is the very late antigen-4
(VLA-4, α4β1integrin, CD49d/CD29), which is a transmem-
brane adhesion receptor. VLA-4 is over-expressed on MM
cells and plays a key role in the adhesion and spreading
through the bone marrow compartment. VLA-4 binds to vas-
cular cell adhesion molecule-1 (VCAM-1) and fibronectin of
bone marrow stromal cells. The PET tracer [64Cu]-CB-
TE1A1P-LLP2 is now under investigation in preclinical
models [48].
Mitochondrial activity
[99mTc]-sestamibi and [99mTc]-tetrofosmin have been devel-
oped for myocardial perfusion SPECT imaging. These com-
pounds consist of a lipophilic monovalent cation, which is
sequestered in the mitochondria by the large negative mem-
brane potential [28]. [99mTc]-sestamibi SPECT has also been
studied in MM and compared with [18 F]-FDG-PET and
MRI. In newly diagnosed MM patients, [18 F]-FDG-PET
detected more focal lesions than [99mTc]-sestamibi
(Table 2B) [49], probably due to better spatial resolution and
different target imaging. Furthermore, [18 F]-FDG-PET and
[99mTc]-sestamibi detected more lesions, including
extramedullary disease, than MRI [49].
Angiogenesis & hypoxia
The increased FDG uptake by malignant MM cells is related to
higher metabolic activity. This might be a consequence of tu-
mour hypoxia resulting from increased O2 consumption by the
malignant MM cells or due to altered micro-vascularisation of
the bone marrow containing plasma cells. Due to hypoxia, hyp-
oxia inducible factor (HIF)-1α and HIF-2α are produced by the
malignant cells or by the surrounding endothelial cells, which
triggers the production of vascular endothelial growth factor
(VEGF), resulting in increased micro-vessel density (MVD)
around the malignant plasma cells. Several studies have shown
that increasedMVD correlates with tumor progression [50–53].
A relatively lowMVD has been observed in smouldering MM,
which increases significantly during disease progression [51].
The PET tracer 1-α-D: −(5-deoxy-5-[18F]-fluoroarabino
furanosyl)-2-nitroimidazole (18F-FAZA), has been developed
for visualizing in vivo tumor hypoxia. Under hypoxic condi-
tions, two nitroimidazole compounds undergo reduction,
forming highly reactive oxygen radicals and binding to macro-
molecules inside the cell. [18F]-FAZA has been used in patients
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with solid tumors, such as head and neck cancers and non-small
cell lung cancers [54, 55]. At our institute, five patients diag-
nosed with relapsingMM based on a positive [18 F]-FDG-PET
scan underwent [18 F]-FAZA scanning. However, enhanced
uptake of [18 F]-FAZA was not demonstrated in any of the
patients, despite the presence of focal disease (Fig. 2a and b)
[14]. These findings suggest that the degree of hypoxia is not
substantially different in MM spots compared to the surround-
ing bone marrow compartment. An alternative approach might
be to use tracers that bind to the VEGF produced by MM cells.
This can be achieved by labeling bevacizumab, a recombinant,
humanised monoclonal antibody that binds with high affinity to
all isoforms of free humanVEGF. Treatment with bevacizumab
is well-established in solid tumors such as colon cancers and
renal cell carcinomas. [89]Zr-bevacizumab PET scanning has
been used to detect solid tumors like breast cancer and demon-
strated positive scans in 96 % of the patients [56]. [89Zr]-
Bevacizumab PET scanning was also performed in five re-
lapsedMM patients (Fig. 2c and d). All the patients had clinical
progression of MM, and positive lesions were detected on
[18 F]-FDG-PET. Unfortunately, no lesions were detected with
[89Zr]-bevacizumab PET scanning in any of the patients.
Discussion
Various nuclear imaging techniques and tracers have been
used for detecting disease activity and bone lesions in newly
diagnosed MM patients, but few studies have been conducted
in relapsed MM patients. Nuclear imaging can be helpful,
especially in relapsed MM because it is frequently difficult
to detect new disease activity with WBX, MRI or bone mar-
row biopsy due to its scattered growth pattern. Additionally,
nuclear imaging can be helpful in determining the response to
treatment, which might have also prognostic significance for
clinical outcome. As shown in Table 1 and Fig. 1, the tracers
used for nuclear imaging target different aspects of the cellular
properties of the plasma cells. Most studies have been per-
formed with [18 F]-FDG-PET. [18 F]-FDG-PET is widely
used and available for patient care. In newly diagnosed MM,
[18 F]-FDG-PET detects more lesions, including
extramedullary disease, compared to WBX and provides use-
ful information about treatment response and outcome.
Currently, WB-CT-scan is replacing WBX as standard care
for the detection of skeleton lesions. The use of nuclear tracers
provides additional information, especially regarding the met-
abolic status of the disease, and can be used for treatment
monitoring. In newly diagnosed MM patients, it has been
shown that complete normalization of the [18 F]-FDG-PET
scan before and after ASCTcorrelates with improved PFS and
OS [12]. For relapsing MM patients, similar results have been
reported in the diagnostic setting, but no conclusive data are
available on treatment outcome, which might be related to the
small number of patients studied. In about 25% of the patients
with relapsingMM, no defects are shown on [18 F]-FDG-PET
scans despite the presence of active disease (Table 2A).
Comparable results have been reported in newly diagnosed
MM patients, indicating that a negative [18 F]-FDG-PET scan
does not exclude disease activity. Various other tracers can be
used to visualize MM activity, as shown in Table 2. [11C]-
Methionine, [11C]-acetate and [11C]-choline are promising
tracers for detecting skeleton lesions. A drawback of these
tracers is the necessity of an on-site cyclotron, which prevents
wide distribution since it has to be applied shortly following
production. [18 F]-Choline, has a longer half-life, is commer-
cially available, and could be a good alternative.
Angiogenesis plays a distinct role in disease progression in
MM [50–52]. Therefore, it seems promising to use tracers
related to this process. Immunohistochemical staining of bone
marrow biopsies of MM patients show increased MVD, in-
creased VEGF expression by plasma cells and increased ex-
pression of HIF-2α by the endothelial cells. However, no
Fig. 2 Various PET imaging in
MM patients. Legend: a. [18 F]-
FDG-PETwith diffuse hotspots in
the skeleton and extramedullary.
b. [18 F]-FAZA of the same
patient as a with no hot spots. c.
[18 F]-FDG-PET, several bone
hot spots. d. [89Zr]-Bevacizumab
of the same patient as c with no
hot spot in the skeleton
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positive scans were obtained in proof of principle work, nei-
ther with [18 F]-FAZA scanning nor with [89Zr]-
bevacizumab PET scanning, despite strongly positive results
with [18 F]-FDG-PET scanning. It has been suggested that
HIF-1α increases immediately in response to hypoxia, where-
as HIF-2α responds to prolonged periods of hypoxia [57]. The
negative results might be related to technical or biological
issues, for example, due the fact that the bone marrow itself
is in a state of low hypoxia, which might hamper detection by
[18 F]-FAZA.
With immunohistochemical staining we detected high
levels of intracellular VEGFa and clear alteration in the mi-
crovasculature, suggesting that the observedVEGF is secreted
by the malignant plasma cells. However, this VEGFa could
not be visualized by [89Zr]–bevacizumab. This is probably
due to the limited concentration resulting from rapid binding
to plasma cells or platelets and the limitations in spatial reso-
lution with the use of 89Zr-tracers. Based on these first find-
ings, both [18 F]-FAZA and [89Zr]-bevacizumab do not ap-
pear to be useful in the work-up of relapsing MM patients.
Future perspectives
Stand-alone MRI is frequently used in the diagnosis of MM,
especially for the spine and pelvis. PET/MRI appears to be a
promising new technique for diagnosis and follow up of my-
eloma patients. It is now possible to perform PET/MRI studies
in which metabolic components are combined with the ana-
tomic components of the MRI. In MM patients, [18 F]-FDG-
PET/CT has been compared to FDG-PET/MRI. Almost all
lesions detected by [18 F]-FDG-PET/CT were also detected
by FDG-PET/MRI [58]. Further investigation and
optimalization of the protocol for PET/MRI is needed to pro-
vide more information about the role of PET/MRI for diag-
nostic purposes and response monitoring in MM. Novel MRI
sequences are now available. For example, diffusion weighted
imaging (DWI) and delayed contrast enhancement (DCE)
seem to improve the diagnostic properties of MRI in MM
patients [59, 60]. Combining PETwith these novel MRI tech-
niques may be valuable for optimal diagnosis and evaluation
of relapsed MM activity.
The tracers discussed in this review might also be useful in
the radio-immunotherapy setting, as described for [68Ga]-
pentixafor. However, a drawbackmight be the negative effects
on normal hematopoietic cells due to the high expression of
CXCR4 on these cells. These negative effects on normal he-
matopoietic cells might be circumvented if this type of radio-
immunotherapy is used in the context of autologous stem cell
transplantation.
In the future, radiolabeled daratumumab might be very
interesting; preclinical data is promising and treatment with
daratumumab is well-tolerated with encouraging results [36,
37]. Also, anti-CD138 might be a promising approach [38].
CD319 also called signaling lymphocytic activation molecule
(SLAM) F7 is a receptor present on immune cells including
plasma cells. The antibody against SLAMF7 is called
elotuzumab. Treatment with this antibody demonstrates prom-
ising results in relapsing MM patients [39]. Like anti-CD38
and anti-CD138, labeling of this antibody might provide dis-
ease information and perhaps to be a new target for radio-
immunotherapy. Furthermore, labeling with [64Cu]-chelates
might also be used in future research. A mice study with
[64Cu]-anti-CD138 showed promising results [61].
Nuclear imaging is of growing importance in the diagnostic
process and follow up of MM patients. It provides important
information regarding the anatomical localization and the met-
abolic activity of the areas of interest. Combining both pieces
of information according to uniform scoring systems will pro-
vide important information for the individual patient but also
for the comparison of future study protocols. Examples are the
five-point scaling score shown by the Italian group [24] and
the combined use of TLG and MTV [23].
In conclusion, nuclear imaging is an important tool for
diagnostic purposes and response monitoring, particularly in
relapsing MM patients. Various nuclear tracers have been de-
veloped to detect bone, bone marrow and extramedullary in-
volvement. In the future, these tracers might also be used for
treatment monitoring, including detection of minimal residual
disease.
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